Plozasiran - Arrowhead Pharmaceuticals
Alternative Names: ARO-APOC3Latest Information Update: 31 Dec 2024
Price :
$50 *
At a glance
- Originator Arrowhead Pharmaceuticals
- Class Antihyperlipidaemics; Small interfering RNA
- Mechanism of Action APOC3 protein expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Hyperlipoproteinaemia type I
- Phase III Hypertriglyceridaemia
- Phase II Dyslipidaemias
Most Recent Events
- 31 Dec 2024 Updated data from a phase II extension trial in Dyslipidemia presented at the American Heart Association Scientific Sessions 2024 (AHA-2024)
- 29 Nov 2024 Phase-III clinical trials in Hypertriglyceridaemia (Treatment-experienced) in France, Germany, Latvia, Latvia, Lithuania, New Zealand (SC) (NCT06347016)
- 29 Nov 2024 Arrowhead Pharmaceuticals initiates a Phase-III clinical trials in Hypertriglyceridaemia (Treatment-experienced) in USA, Australia, Bulgaria, Canada, Czech Republic, Hungary, Poland, Slovakia and UK (SC) (NCT06347016)